Korea Cuts Novartis’ Glivec Price By 14 Percent - Tip Of The Iceberg For MNCs In Korea?
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs announced it will cut the price of Swiss-based Novartis' leukemia drug Glivec (imatinib) by 14 percent. The move is the ministry's first reaction to criticism from patient advocacy groups over inflated prices of multinational drug makers' products